NIH/NCI R01-
Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML (2023-2028)
NIH/NCI-R01-
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer (2020-2025)
Alex’s Lemonade Stand Foundation (ALSF)-
Feasibility study of dual inhibition of MDM2 and tubulin in treatment of AML (2023-2025)
The Andrew McDonough B+ Foundation-
Discovery of novel MDM2-targeted therapy for pediatric AML (2023-2025)
CURE Childhood Cancer-
Feasibility study of VERU-111 for precision treatment of pediatric AML (2022-2024)